Lansoprazole Viatris

Lansoprazole, the active ingredient in Lansoprazole Viatris, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to manage acid‑related disorders such as gastro‑esophageal reflux disease, erosive esophagitis, and peptic ulcer disease in adult patients.

GNH USA supplies Lansoprazole Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this essential medication.

Lansoprazole is indicated for several acid‑related conditions affecting the gastrointestinal tract. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by maintaining higher gastric pH. - Erosive esophagitis: promotes healing of inflamed esophageal tissue. - Peptic ulcer disease: supports ulcer healing and prevents recurrence. - Helicobacter pylori eradication regimen: used in combination therapy to increase eradication rates.

Lansoprazole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Diarrhea: loose or watery stools. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort in the stomach area. - Flatulence: excess gas in the gastrointestinal tract.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with diarrhea. - Acute interstitial nephritis: kidney inflammation causing reduced function. - Hepatic injury: elevated liver enzymes or jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Bone fracture: increased risk with long‑term use.

When prescribing or dispensing Lansoprazole, consider the following precautions to ensure safe use. - Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate for CYP2C19 interactions: genetic variations can affect drug levels. - Monitor long‑term use: prolonged therapy may increase risk of fractures and vitamin B12 deficiency. - Use cautiously in patients with liver disease: hepatic impairment can alter metabolism. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Store at room temperature: keep below 25°C in the original container, protect from moisture.

Lansoprazole can affect the plasma concentrations of several concomitant medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect when co‑administered. - Atazanavir: decreased absorption leading to therapeutic failure. - Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation. - Digoxin: altered absorption, check serum levels. - Diazepam: increased plasma concentration, observe for sedation.